ArticleTherapeutic advances in medical oncology2026
The association between cardiovascular medication use and survival in patients with advanced pancreatic adenocarcinoma.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between preoperative statin use and survival after pylorus-preserving pancreaticoduodenectomy for pancreatic or periampullary cancer: a propensity score-matched cohort study.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advanced pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and limited therapeutic options. Drug repurposing offers a cost-effective strategy to identify agents with potential synergistic benefits and known safety profiles. Preclinical and retrospective studies suggest that renin-angiotensin-aldosterone system inhibitors (RAASi) and statins may enhance chemotherapy efficacy by modulating the tumor microenvironment and oncogenic signaling. Objectives: To explore associations between cumulative RAASi and/or statin use and overall survival (OS) in elderly patients with advanced PDAC receiving first-line chemotherapy, as hypothesis-generating adjunct exposures. Methods: We analyzed a population-based registry using linked administrative databases from Ontario, Canada, identifying patients aged ⩾67 years with advanced PDAC who received first-line gemcitabine/nab-paclitaxel or mFOLFIRINOX between 2015 and 2024. The primary outcome was OS. Associations between cumulative RAASi or statin exposure and OS were assessed using multivariable Cox proportional hazards models, treating cumulative drug exposure as a time-varying covariate to mitigate immortal time bias. Results: Among 3226 eligible patients, the median age was 73 years, and 44% were female. Forty-one percent received both RAASi and statins, 17% statins alone, 14% RAASi alone, and 28% neither. Median OS was 7.9 months across groups. On multivariable analysis, neither cumulative RAASi (hazard ratio (HR) 1.00, 95% CI 0.98-1.02) nor statin exposure (HR 1.00, 95% CI 0.98-1.02) was associated with improved survival. Conclusion: In this large cohort of advanced PDAC patients undergoing first-line chemotherapy, real-world, non-targeted RAASi and statin use was not associated with improved OS. These findings highlight the need for rigorously designed prospective studies to validate repurposed drug candidates before clinical adoption. Design: Retrospective population-based cohort study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.